<!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Archiving and Interchange DTD v1.0 20120330//EN" "JATS-archivearticle1.dtd">
<article xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" article-type="research-article" xml:lang="en"><?properties open_access?><front><journal-meta><journal-id journal-id-type="nlm-ta">Parasit Vectors</journal-id><journal-id journal-id-type="iso-abbrev">Parasit Vectors</journal-id><journal-title-group><journal-title>Parasites &#x00026; Vectors</journal-title></journal-title-group><issn pub-type="epub">1756-3305</issn><publisher><publisher-name>BioMed Central</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="pmid">23289920</article-id><article-id pub-id-type="pmc">3558385</article-id><article-id pub-id-type="publisher-id">1756-3305-6-3</article-id><article-id pub-id-type="doi">10.1186/1756-3305-6-3</article-id><article-categories><subj-group subj-group-type="heading"><subject>Research</subject></subj-group></article-categories><title-group><article-title>Prevalence of intestinal protozoa infection among school-aged children on Pemba Island, Tanzania, and effect of single-dose albendazole, nitazoxanide and albendazole-nitazoxanide</article-title></title-group><contrib-group><contrib contrib-type="author" id="A1"><name><surname>Speich</surname><given-names>Benjamin</given-names></name><xref ref-type="aff" rid="I1">1</xref><xref ref-type="aff" rid="I2">2</xref><email>benjamin.speich@unibas.ch</email></contrib><contrib contrib-type="author" id="A2"><name><surname>Marti</surname><given-names>Hanspeter</given-names></name><xref ref-type="aff" rid="I2">2</xref><xref ref-type="aff" rid="I3">3</xref><email>hanspeter.marti@unibas.ch</email></contrib><contrib contrib-type="author" id="A3"><name><surname>Ame</surname><given-names>Shaali M</given-names></name><xref ref-type="aff" rid="I4">4</xref><email>shaaliame@yahoo.com</email></contrib><contrib contrib-type="author" id="A4"><name><surname>Ali</surname><given-names>Said M</given-names></name><xref ref-type="aff" rid="I4">4</xref><email>saidmali2003@yahoo.com</email></contrib><contrib contrib-type="author" id="A5"><name><surname>Bogoch</surname><given-names>Isaac I</given-names></name><xref ref-type="aff" rid="I5">5</xref><email>ibogoch@hotmail.com</email></contrib><contrib contrib-type="author" id="A6"><name><surname>Utzinger</surname><given-names>J&#x000fc;rg</given-names></name><xref ref-type="aff" rid="I2">2</xref><xref ref-type="aff" rid="I6">6</xref><email>juerg.utzinger@unibas.ch</email></contrib><contrib contrib-type="author" id="A7"><name><surname>Albonico</surname><given-names>Marco</given-names></name><xref ref-type="aff" rid="I7">7</xref><email>albonico@tin.it</email></contrib><contrib contrib-type="author" corresp="yes" id="A8"><name><surname>Keiser</surname><given-names>Jennifer</given-names></name><xref ref-type="aff" rid="I1">1</xref><xref ref-type="aff" rid="I2">2</xref><email>jennifer.keiser@unibas.ch</email></contrib></contrib-group><aff id="I1"><label>1</label>Department of Medical Parasitology and Infection Biology, Swiss Tropical and Public Health Institute, P.O. Box, CH-4002, Basel, Switzerland</aff><aff id="I2"><label>2</label>University of Basel, P.O. Box, CH-4003, Basel, Switzerland</aff><aff id="I3"><label>3</label>Department of Medical and Diagnostic Services, Swiss Tropical and Public Health Institute, P.O. Box, CH-4002, Basel, Switzerland</aff><aff id="I4"><label>4</label>Public Health Laboratory (Pemba)-Ivo de Carneri, P.O. Box, TZ-122, Wawi, Chake Chake, Tanzania</aff><aff id="I5"><label>5</label>Divisions of Internal Medicine and Infectious Diseases, Toronto General Hospital, Toronto, Ontario, Canada</aff><aff id="I6"><label>6</label>Department of Epidemiology and Public Health, Swiss Tropical and Public Health Institute, P.O. Box, CH-4002, Basel, Switzerland</aff><aff id="I7"><label>7</label>Ivo de Carneri Foundation, P.O. Box, IT-10122, Milan, Italy</aff><pub-date pub-type="collection"><year>2013</year></pub-date><pub-date pub-type="epub"><day>4</day><month>1</month><year>2013</year></pub-date><volume>6</volume><fpage>3</fpage><lpage>3</lpage><history><date date-type="received"><day>13</day><month>12</month><year>2012</year></date><date date-type="accepted"><day>25</day><month>12</month><year>2012</year></date></history><permissions><copyright-statement>Copyright &#x000a9;2013 Speich et al.; licensee BioMed Central Ltd.</copyright-statement><copyright-year>2013</copyright-year><copyright-holder>Speich et al.; licensee BioMed Central Ltd.</copyright-holder><license license-type="open-access" xlink:href="http://creativecommons.org/licenses/by/2.0"><license-p>This is an Open Access article distributed under the terms of the Creative Commons Attribution License (
<ext-link ext-link-type="uri" xlink:href="http://creativecommons.org/licenses/by/2.0">http://creativecommons.org/licenses/by/2.0</ext-link>), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.</license-p></license></permissions><self-uri xlink:href="http://"/><abstract><sec><title>Background</title><p>Pathogenic intestinal protozoa infections are common in school-aged children in the developing world and they are frequently associated with malabsorption syndromes and gastrointestinal morbidity. Since diagnosis of these parasites is difficult, prevalence data on intestinal protozoa is scarce.</p></sec><sec><title>Methods</title><p>We collected two stool samples from school-aged children on Pemba Island, Tanzania, as part of a randomized controlled trial before and 3 weeks after treatment with (i) single-dose albendazole (400 mg); (ii) single-dose nitazoxanide (1,000 mg); (iii) nitazoxanide-albendazole combination (1,000 mg&#x02013;400 mg), with each drug given separately on two consecutive days; and (iv) placebo. Formalin-fixed stool samples were examined for the presence of intestinal protozoa using an ether-concentration method to determine the prevalence and estimate cure rates (CRs).</p></sec><sec><title>Results</title><p>Almost half (48.7%) of the children were diagnosed with at least one of the (potentially) pathogenic protozoa <italic>Giardia intestinalis</italic>, <italic>Entamoeba histolytica/E. dispar</italic> and <italic>Blastocystis hominis.</italic> Observed CRs were high for all treatment arms, including placebo. Nitazoxanide showed a significant effect compared to placebo against the non-pathogenic protozoon <italic>Entamoeba coli.</italic></p></sec><sec><title>Conclusions</title><p>Intestinal protozoa infections might be of substantial health relevance even in settings where they are not considered as a health problem. Examination of a single stool sample with the ether-concentration method lacks sensitivity for the diagnosis of intestinal protozoa, and hence, care is indicated when interpreting prevalence estimates and treatment effects.</p></sec></abstract><kwd-group><kwd>Intestinal protozoa</kwd><kwd><italic>Blastocystis hominis</italic></kwd><kwd><italic>Entamoeba histolytica/E. dispar</italic></kwd><kwd><italic>Giardia intestinalis</italic></kwd><kwd>Albendazole</kwd><kwd>Nitazoxanide</kwd><kwd>Ether-concentration method</kwd></kwd-group></article-meta></front><body><sec><title>Background</title><p>Infection with pathogenic intestinal protozoa (e.g. <italic>Entamoeba histolytica</italic> and <italic>Giardia intestinalis</italic>) result in considerable gastrointestinal morbidity, malnutrition and mortality worldwide, particularly among young children in developing countries 
[<xref ref-type="bibr" rid="B1">1</xref>,<xref ref-type="bibr" rid="B2">2</xref>]. It has been estimated that <italic>E. histolytica</italic>, the causative agent of amoebiasis, kills between 40,000 and 100,000 people each year; hence, is one of the deadliest parasitic infections worldwide 
[<xref ref-type="bibr" rid="B2">2</xref>,<xref ref-type="bibr" rid="B3">3</xref>]. In the People&#x02019;s Republic of China alone, <italic>G. intestinalis</italic> affects an estimated 28.5 million people every year 
[<xref ref-type="bibr" rid="B1">1</xref>]. The prevalence of <italic>G. intestinalis</italic> has been estimated at 2&#x02013;3% in the industrialized world and 20&#x02013;30% in developing countries 
[<xref ref-type="bibr" rid="B4">4</xref>]. <italic>Cryptosporidium</italic> spp<italic>.</italic> is another major causal agent of diarrhoea, primarily affecting immunocompromised individuals such as those infected with HIV 
[<xref ref-type="bibr" rid="B3">3</xref>,<xref ref-type="bibr" rid="B5">5</xref>,<xref ref-type="bibr" rid="B6">6</xref>]. <italic>Blastocystis hominis</italic> is a common additional anaerobic intestinal protozoon and its pathogenicity is still under debate 
[<xref ref-type="bibr" rid="B7">7</xref>-<xref ref-type="bibr" rid="B9">9</xref>]. Lack of access to clean water, sanitation and hygiene are strong drivers for infection with intestinal protozoa 
[<xref ref-type="bibr" rid="B10">10</xref>-<xref ref-type="bibr" rid="B12">12</xref>].</p><p>Several drugs are currently available to treat intestinal protozoa infections. Most commonly used are 5-nitroimidazole compounds, including metronidazole, tinidazole, ornidazole and secnidazole 
[<xref ref-type="bibr" rid="B13">13</xref>]. Alternative effective agents, when given as multiple doses, include nitazoxanide and albendazole 
[<xref ref-type="bibr" rid="B14">14</xref>-<xref ref-type="bibr" rid="B16">16</xref>].</p><p>Information on the prevalence of intestinal protozoa infections is scarce and little data are available from sub-Saharan Africa. For example, to the best of our knowledge, the prevalence of intestinal protozoa infections on Pemba Island has been assessed only twice and these investigations date back to 1984 and 1992 
[<xref ref-type="bibr" rid="B17">17</xref>,<xref ref-type="bibr" rid="B18">18</xref>]. In the 1984 study, the prevalence of <italic>G. intestinalis</italic> and <italic>E. histolytica</italic> among children and adults combined were 5.6% and 3.1%, respectively. Prevalences of 35.6%, 4.4%, 2.9%, 0.7% and 0.7% were reported for <italic>Entamoeba coli</italic>, <italic>Endolimax nana</italic>, <italic>Chilomastix mesnili</italic>, <italic>Entamoeba hartmanni</italic> and <italic>Iodamoeba b&#x000fc;tschlii,</italic> respectively (Figure&#x02009;
<xref ref-type="fig" rid="F1">1</xref>) 
[<xref ref-type="bibr" rid="B17">17</xref>]. The study conducted in 1992 reported prevalences of 25.4% for <italic>E. histolytica</italic> and 6.6% for <italic>G. intestinalis</italic> among children aged 9&#x02013;17 years 
[<xref ref-type="bibr" rid="B18">18</xref>].</p><fig id="F1" position="float"><label>Figure 1</label><caption><p><bold>Comparison of prevalence of intestinal protozoa infections assessed in mid-2011 at baseline, 3 weeks post-treatment follow-up and combined results (current study) against prevalence determined in 1984 (study done by Pampiglione</bold><bold><italic>et al.</italic></bold><bold>[</bold>[<xref ref-type="bibr" rid="B17">17</xref>]<bold>]</bold><bold>) on Pemba Island, Tanzania.</bold></p></caption><graphic xlink:href="1756-3305-6-3-1"/></fig><p>The study reported here was integrated in a randomized controlled trial carried out in school-aged children on Pemba Island, Tanzania in mid-2011 to asses the efficacy and safety of single-dose nitazoxanide and albendazole and a nitazoxanide-albendazole combination against <italic>Trichuris trichiura</italic> and other soil-transmitted helminth infections 
[<xref ref-type="bibr" rid="B19">19</xref>]. The aim of the present work was to evaluate the prevalence of intestinal protozoa infections in these children and to determine whether the study drugs had an effect on intestinal protozoa. Throughout the study, the ether-concentration method was used on formalin-fixed stool samples.</p></sec><sec sec-type="methods"><title>Methods</title><sec><title>Ethics statement</title><p>Our randomized controlled trial was approved by the ethics committee of Basel (EKBB; reference no. 225/10), and the Ministry of Health and Social Welfare of Zanzibar (ZAMREC; reference no. 0001/010) and is registered at Current Controlled Trials (trial identifier: ISRCTN08336605). Participating in the trial required written informed consent from parents or legal guardians and oral assent from children. Parents and children were counseled that participation is voluntary and withdrawal was possible at any time without specification of reasons and further obligations. At the end of the trial, all children who were diagnosed with soil-transmitted helminths received albendazole (single oral dose of 400 mg).</p></sec><sec><title>Study area and design</title><p>Details of the study area, population and procedures have been described previously 
[<xref ref-type="bibr" rid="B19">19</xref>]. In brief, the study was carried out in June and July 2011 in children aged 7&#x02013;15 years attending two schools (Wawi and Al-Sadik) located within a radius of 10 km from Chake Chake, the main city of Pemba Island. The study was a randomized controlled trial with four treatment arms: (i) single-dose albendazole (400 mg); (ii) single-dose nitazoxanide (1,000 mg); (iii) nitazoxanide-albendazole combination (1,000 mg&#x02013;400 mg) with each drug given separately on two consecutive days; and (iv) placebo. Of the 657 children, who completed the trial, 550 (83.7%) had formalin-fixed stool samples before and after treatment and were therefore included in the present study (treatment arms: (i) n = 136, (ii) n = 145, (iii) n = 117, and (iv) n = 152; Wawi school: n = 404, Al-Sadik school: n = 146).</p></sec><sec><title>Procedures for the diagnosis of intestinal protozoa</title><p>Approximately 2&#x02009;g of stool were fixed in 10&#x02009;ml of 5% formalin in Falcon tubes labeled with unique identifiers. Stool samples were thoroughly broken down and homogenized with a wooden spatula. The formalin-fixed samples were transferred to the Swiss Tropical and Public Health Institute (Basel, Switzerland) and examined within 10&#x02009;months.</p><p>The fixed stool samples were processed with an ether-concentration method 
[<xref ref-type="bibr" rid="B20">20</xref>,<xref ref-type="bibr" rid="B21">21</xref>]. Briefly, the homogenized stool sample was filtered through a medical gauze into a new tube and then centrifuged for 1 min at 500 <italic>g</italic>. The supernatant was discarded. To the remaining pellet, 7 ml of physiological NaCl-solution and 2&#x02013;3 ml of diethyl ether was added. Tubes were shaken and centrifuged again for 3 min at 500 <italic>g</italic>. The upper three layers were discarded. The entire sediment was examined by experienced laboratory technicians under a microscope for soil-transmitted helminths at a magnification of 100&#x000d7;, and intestinal protozoa at a magnification of 400&#x000d7; or 500&#x000d7; using oil immersion. The current analysis focuses on intestinal protozoa, including the pathogenic intestinal protozoa <italic>G. intestinalis</italic> and <italic>E. histolytica</italic>/<italic>E. dispar</italic> (of note, these two <italic>Entamoeba</italic> species cannot be differentiated by microscopy 
[<xref ref-type="bibr" rid="B22">22</xref>]); the potentially pathogenic protozoon <italic>B. hominis</italic>, and the non-pathogenic protozoa <italic>E. coli</italic>, <italic>E. hartmanni</italic>, <italic>E. nana</italic>, <italic>C. mesnili</italic> and <italic>I. b&#x000fc;tschlii</italic>[<xref ref-type="bibr" rid="B7">7</xref>-<xref ref-type="bibr" rid="B9">9</xref>,<xref ref-type="bibr" rid="B23">23</xref>]. <italic>Cryptosporidium</italic> spp. was not included, since it cannot easily be detected with the formalin-ether concentration technique, and would have required staining with the modified Ziehl-Neelsen method 
[<xref ref-type="bibr" rid="B24">24</xref>]. Infection intensities were classified as follows: (i) negative (no cysts or trophozoites in the entire sediment); (ii) light (one to five cysts or trophozoites per slide); (iii) moderate (one cyst or trophozoite per observation field at the 400&#x000d7; or 500&#x000d7; magnification); and (iv) heavy (more than one cyst or trophozoite per observation field) 
[<xref ref-type="bibr" rid="B21">21</xref>,<xref ref-type="bibr" rid="B25">25</xref>].</p></sec><sec><title>Statistical analysis</title><p>Data were double-entered into an Excel file (Microsoft 2010) and cross-checked. Statistical analysis was performed using Stata version 10.1 (StataCorp; College Station, USA).</p><p>The prevalence of intestinal protozoa was determined before treatment (baseline) and at the 3-week post-treatment follow-up. Differences between prevalence at baseline and follow-up were assessed using <italic>x</italic><sup>2</sup> test. In the baseline prevalence analyses, the odds of being infected with a specific intestinal protozoon species for boys compared to girls and for children from Wawi compared to Al-Sadik school was calculated using logistic regression.</p><p>Cure rates (CRs) were estimated for each intestinal protozoon species for the different treatment arms as the percentage of positive children at baseline diagnosed negative after treatment. Differences in CRs among treatment arms were examined using logistic regressions. Reduction of infection intensity was assessed as the difference in infection intensities before and after treatment among all individuals (negative individuals before treatment were included in the analysis). Mean of differences in infection intensities was calculated for each treatment arm and for each intestinal protozoon species together with 95% confidence intervals (CIs). Decrease in infection intensity was assumed as significant when 95% CI was below 0.</p></sec></sec><sec sec-type="results"><title>Results</title><sec><title>Prevalence and intensity of intestinal protozoa infection</title><p>Based on the analysis of one formalin-fixed stool sample per child at baseline, 74.7% of the children harboured at least one intestinal protozoa species. About half of the children (48.7%) were infected with at least one of the three (potentially) pathogenic intestinal protozoa. The prevalence of <italic>E. histolytica/E. dispar</italic> and <italic>G. intestinalis</italic> was 18.0% and 16.4%, respectively before treatment (Table&#x02009;
<xref ref-type="table" rid="T1">1</xref>). The potentially pathogenic intestinal protozoon <italic>B. hominis</italic> was diagnosed in 28.0% of the children. Prevalences for the other intestinal protozoa were 51.5% for <italic>E. coli</italic>, 19.5% for <italic>E. nana</italic>, 13.3% for <italic>E. hartmanni</italic>, 8.2% for <italic>C. mesnili</italic> and 6.7% for <italic>I. b&#x000fc;tschlii.</italic> For the pathogenic intestinal protozoon <italic>G. intestinalis</italic>, 44.4%, 38.9% and 16.7% of the infections were classified as light, moderate and heavy, respectively. The infection intensities of other intestinal protozoa species are listed in Table&#x02009;
<xref ref-type="table" rid="T1">1</xref>.</p><table-wrap position="float" id="T1"><label>Table 1</label><caption><p>Baseline characteristics of included school-aged children on Pemba Island in mid-2011 with regard to intestinal protozoa infection</p></caption><table frame="hsides" rules="groups" border="1"><colgroup><col align="left"/><col align="center"/><col align="center"/><col align="center"/></colgroup><thead><tr><th align="left" valign="bottom"><bold>Characteristic, intestinal protozoa</bold><hr/></th><th align="center" valign="bottom"><bold>N (prevalence in %)</bold><hr/></th><th align="center" valign="bottom"><bold>Girls (%)/boys (%)</bold><hr/></th><th align="center" valign="bottom"><bold>Wawi (%)/Al-Sadik school (%)</bold><hr/></th></tr><tr><th align="left">&#x000a0;</th><th align="center"><bold>low (%)/moderate (%)/heavy (%)</bold></th><th align="center">&#x000a0;</th><th align="center">&#x000a0;</th></tr></thead><tbody><tr><td align="left" valign="top">No. of children tested<hr/></td><td align="center" valign="bottom">550<hr/></td><td align="center" valign="bottom">271/279<hr/></td><td align="center" valign="bottom">404/146<hr/></td></tr><tr><td rowspan="2" align="left" valign="top"><italic>G. intestinalis</italic><hr/></td><td align="center" valign="bottom">90 (16.4)<hr/></td><td rowspan="2" align="center" valign="bottom">37 (13.7)/53 (19.0)<hr/></td><td rowspan="2" align="center" valign="bottom">59 (14.6)/31 (21.1)<hr/></td></tr><tr><td align="center" valign="bottom">40 (44.4)/35 (38.9)/15 (16.7)<hr/></td></tr><tr><td rowspan="2" align="left" valign="top"><italic>E. histolytica/E. dispar</italic><hr/></td><td align="center" valign="bottom">99 (18.0)<hr/></td><td rowspan="2" align="center" valign="bottom">53 (19.6)/46 (16.5)<hr/></td><td rowspan="2" align="center" valign="bottom">77 (19.1)/22 (15.1)<hr/></td></tr><tr><td align="center" valign="bottom">57 (57.6)/33 (33.3)/9 (9.1)<hr/></td></tr><tr><td rowspan="2" align="left" valign="top"><italic>B. hominis</italic><hr/></td><td align="center" valign="bottom">154 (28.0)<hr/></td><td rowspan="2" align="center" valign="bottom">73 (26.9)/81 (29.0)<hr/></td><td rowspan="2" align="center" valign="bottom">103 (34.9)/51 (25.5)<hr/></td></tr><tr><td align="center" valign="bottom">125 (81.2)/25 (16.2)/4 (2.6)<hr/></td></tr><tr><td align="left" valign="top"><italic>E. coli</italic><hr/></td><td align="center" valign="bottom">283 (51.5)<hr/></td><td align="center" valign="bottom">151 (55.7)/132 (47.3)<hr/></td><td align="center" valign="bottom">210 (52.0)/73 (50.0)<hr/></td></tr><tr><td align="left" valign="bottom">&#x000a0;<hr/></td><td align="center" valign="bottom">101 (35.7)/104 (36.7)/78 (27.6)<hr/></td><td align="center" valign="bottom">&#x000a0;<hr/></td><td align="center" valign="bottom">&#x000a0;<hr/></td></tr><tr><td align="left" valign="top"><italic>E. nana</italic><hr/></td><td align="center" valign="bottom">107 (19.5)<hr/></td><td align="center" valign="bottom">58 (21.4)/49 (17.6)<hr/></td><td align="center" valign="bottom">71 (17.6)/36 (24.7)<hr/></td></tr><tr><td align="left" valign="bottom">&#x000a0;<hr/></td><td align="center" valign="bottom">62 (57.9)/40 (37.4)/5 (4.7)<hr/></td><td align="center" valign="bottom">&#x000a0;<hr/></td><td align="center" valign="bottom">&#x000a0;<hr/></td></tr><tr><td align="left" valign="top"><italic>E. hartmanni</italic><hr/></td><td align="center" valign="bottom">73 (13.3)<hr/></td><td align="center" valign="bottom">38 (14.0)/35 (12.0)<hr/></td><td align="center" valign="bottom">52 (12.9)/21 (14.4)<hr/></td></tr><tr><td align="left" valign="bottom">&#x000a0;<hr/></td><td align="center" valign="bottom">57 (78.1)/14 (19.2)/2 (2.7)<hr/></td><td align="center" valign="bottom">&#x000a0;<hr/></td><td align="center" valign="bottom">&#x000a0;<hr/></td></tr><tr><td align="left" valign="top"><italic>C. mesnili</italic><hr/></td><td align="center" valign="bottom">45 (8.2)<hr/></td><td align="center" valign="bottom">27 (6.5)/18 (10.0)<hr/></td><td align="center" valign="bottom">31 (7.7)/14 (9.6)<hr/></td></tr><tr><td align="left" valign="bottom">&#x000a0;<hr/></td><td align="center" valign="bottom">21 (46.7)/18 (40.0)/6 (13.3)<hr/></td><td align="center" valign="bottom">&#x000a0;<hr/></td><td align="center" valign="bottom">&#x000a0;<hr/></td></tr><tr><td align="left" valign="top"><italic>I. b&#x000fc;tschlii</italic><hr/></td><td align="center" valign="bottom">37 (6.7)<hr/></td><td align="center" valign="bottom">18 (6.6)/19 (6.8)<hr/></td><td align="center" valign="bottom">22 (5.4)/15 (10.3)<hr/></td></tr><tr><td align="left" valign="bottom">&#x000a0;<hr/></td><td align="center" valign="bottom">31 (83.8)/5 (13.5)/1 (2.7)<hr/></td><td align="center" valign="bottom">&#x000a0;<hr/></td><td align="center" valign="bottom">&#x000a0;<hr/></td></tr><tr><td align="left" valign="top"><italic>G. intestinalis</italic> or <italic>E. histolytica/E. dispar</italic> or <italic>B. hominis</italic><hr/></td><td align="center" valign="bottom">268 (48.7)<hr/></td><td align="center" valign="bottom">135 (49.8)/133 (47.8)<hr/></td><td align="center" valign="bottom">187 (46.3)/81 (55.5)<hr/></td></tr><tr><td align="left" valign="top">Any intestinal protozoa</td><td align="center">411 (74.4)</td><td align="center">219 (80.8)/192 (68.8)</td><td align="center">297 (73.5)/114 (78.1)</td></tr></tbody></table></table-wrap><p>Examination of the follow-up stool samples revealed the following prevalences: 49.8% of children remained infected with at least one of the three (potentially) pathogenic intestinal protozoa and 69.3% of the children were found positive for at least one intestinal protozoa. The prevalence of <italic>G. intestinalis</italic>, <italic>E. histolytica/E. dispar</italic> and <italic>B. hominis</italic> at the 3-week post-treatment follow-up was 17.3%, 16.4% and 31.1%, respectively (Figure&#x02009;
<xref ref-type="fig" rid="F1">1</xref>). Prevalence for the non-pathogenic intestinal protozoa species were 42.9% for <italic>E. coli</italic>, 17.5% for <italic>E. nana</italic>, 12.9% for <italic>E. hartmanni</italic>, 8.2% for <italic>I. b&#x000fc;tschlii</italic> and 6.7% for <italic>C. mesnili.</italic> According to the <italic>x</italic><sup>2</sup> test, only <italic>E. coli</italic> (<italic>p</italic> = 0.004) and all intestinal protozoa combined (<italic>p</italic> = 0.046) showed significantly lower prevalence at follow-up compared to baseline.</p><p>The odds of being infected with any intestinal protozoa at baseline was significantly higher for girls than boys (odds ratio (OR) = 1.97; 95% CI 1.32&#x02013;2.93) (Table&#x02009;
<xref ref-type="table" rid="T2">2</xref>). There was a trend (<italic>p</italic> &#x0003c;0.1) that girls were at a higher odds of being infected with <italic>E. coli</italic> than boys (OR = 1.40; 95% CI 1.00&#x02013;1.96). Children from Wawi school had significantly lower odds of being infected with <italic>B. hominis</italic> (OR = 0.64; 95% CI 0.43-0.97), <italic>E. nana</italic> (OR = 0.63; 95% CI 0.40&#x02013;1.00) and <italic>I. b&#x000fc;tschlii</italic> (OR = 0.50; 95% CI 0.25&#x02013;1.00) considering only the baseline stool sample than children from Al-Sadik. Additionally, there was a trend (<italic>p</italic> &#x0003c;0.1) that children from Wawi school had a lower odds of being infected with <italic>G. intestinalis</italic> (OR = 0.66; 95% CI 0.41&#x02013;1.07) and any of the three (potentially) pathogenic intestinal protozoa combined (OR = 0.68; 95% CI 0.47&#x02013;1.00).</p><table-wrap position="float" id="T2"><label>Table 2</label><caption><p>Odds ratios (OR) of being infected with intestinal protozoa among school-aged children on Pemba Island in mid-2011, as assessed by logistic regression</p></caption><table frame="hsides" rules="groups" border="1"><colgroup><col align="left"/><col align="center"/><col align="center"/></colgroup><thead><tr><th align="left"><bold>Intestinal protozoa</bold></th><th align="center"><bold>OR girls vs. boys (95% CI)</bold></th><th align="center"><bold>OR Wawi vs. Al-Sadik school (95% CI)</bold></th></tr></thead><tbody><tr><td align="left" valign="bottom"><italic>G. intestinalis</italic><hr/></td><td align="char" valign="bottom" char="(">0.67 (0.44&#x02013;1.11)<hr/></td><td align="char" valign="bottom" char="(">0.66 (0.41&#x02013;1.07)<hr/></td></tr><tr><td align="left" valign="bottom"><italic>E. histolytica/E. dispar</italic><hr/></td><td align="char" valign="bottom" char="(">1.21 (0.78&#x02013;1.87)<hr/></td><td align="char" valign="bottom" char="(">1.30 (0.77&#x02013;2.19)<hr/></td></tr><tr><td align="left" valign="bottom"><italic>B. hominis</italic><hr/></td><td align="char" valign="bottom" char="(">0.94 (0.64&#x02013;1.37)<hr/></td><td align="char" valign="bottom" char="(">0.64 (0.43&#x02013;0.97)*<hr/></td></tr><tr><td align="left" valign="bottom"><italic>E. coli</italic><hr/></td><td align="char" valign="bottom" char="(">1.40 (1.00&#x02013;1.96)<hr/></td><td align="char" valign="bottom" char="(">1.04 (0.71&#x02013;1.53)<hr/></td></tr><tr><td align="left" valign="bottom"><italic>E. nana</italic><hr/></td><td align="char" valign="bottom" char="(">1.34 (0.87&#x02013;2.05)<hr/></td><td align="char" valign="bottom" char="(">0.63 (0.40&#x02013;1.00)*<hr/></td></tr><tr><td align="left" valign="bottom"><italic>E. hartmanni</italic><hr/></td><td align="char" valign="bottom" char="(">1.15 (0.70&#x02013;1.89)<hr/></td><td align="char" valign="bottom" char="(">0.87 (0.50&#x02013;1.50)<hr/></td></tr><tr><td align="left" valign="bottom"><italic>C. mesnili</italic><hr/></td><td align="char" valign="bottom" char="(">1.65 (0.88&#x02013;3.09)<hr/></td><td align="char" valign="bottom" char="(">0.74 (0.38&#x02013;1.44)<hr/></td></tr><tr><td align="left" valign="bottom"><italic>I. b&#x000fc;tschlii</italic><hr/></td><td align="char" valign="bottom" char="(">1.04 (0.53&#x02013;2.04)<hr/></td><td align="char" valign="bottom" char="(">0.50 (0.25&#x02013;1.00)*<hr/></td></tr><tr><td align="left" valign="bottom"><italic>G. intestinalis</italic> or <italic>E. histolytica/E. dispar</italic> or <italic>B. hominis</italic><hr/></td><td align="char" valign="bottom" char="(">1.13 (0.81&#x02013;1.58)<hr/></td><td align="char" valign="bottom" char="(">0.68 (0.47&#x02013;1.00)<hr/></td></tr><tr><td align="left">Any intestinal protozoa</td><td align="char" char="(">1.97 (1.32&#x02013;2.93)*</td><td align="char" char="(">0.72 (0.46&#x02013;1.14)</td></tr></tbody></table><table-wrap-foot><p>*<italic>p</italic> &#x0003c;0.05.</p><p>CI, confidence interval.</p></table-wrap-foot></table-wrap></sec><sec><title>Effect of antiparasitic treatment against intestinal protozoa</title><p>Observed CRs were moderate to high for all intestinal protozoa regardless of the treatments administered (Table&#x02009;
<xref ref-type="table" rid="T3">3</xref>). The highest CR was observed for the albendazole-nitazoxanide combination against <italic>E. nana</italic> (CR 91.3%; 95% CI 78.8&#x02013;100.0%)<italic>.</italic> The lowest CR among the antiparasitics tested was documented for single-dose albendazole against <italic>E. coli</italic> (CR 33.3%; 95% CI 22.4&#x02013;44.3%). Note that the group of children receiving placebo had moderate to high CRs against intestinal protozoa infections. Comparing the outcomes among treatment arms using logistic regression revealed that single-dose nitazoxanide had a significant effect on <italic>E. coli</italic> (OR = 0.35; 95% CI 0.18&#x02013;0.68). Furthermore, we observed a trend (<italic>p</italic> &#x0003c;0.1) with the combination of nitazoxanide plus albendazole against <italic>E. nana</italic> (OR = 0.18; 95% CI 0.02&#x02013;1.27). All other results of the logistic regressions revealed p-values above 0.1; hence, there was no significant effect compared to placebo.</p><table-wrap position="float" id="T3"><label>Table 3</label><caption><p>Effect of albendazole, nitazoxanide, sequentially administered albendazole-nitazoxanide combination, and placebo against intestinal protozoa infections among school-aged children on Pemba Island in mid-2011</p></caption><table frame="hsides" rules="groups" border="1"><colgroup><col align="left"/><col align="center"/><col align="center"/><col align="center"/><col align="center"/></colgroup><thead><tr><th align="left"><bold>Characteristic</bold></th><th align="center"><bold>Single-dose albendazole</bold></th><th align="center"><bold>Single-dose nitazoxanide</bold></th><th align="center"><bold>Nitazoxanide-albendazole combination</bold></th><th align="center"><bold>Placebo</bold></th></tr></thead><tbody><tr><td colspan="5" align="left" valign="bottom"><bold><italic>G. intestinalis</italic></bold><hr/></td></tr><tr><td align="left" valign="bottom">No. of infected children<hr/></td><td align="center" valign="bottom">25<hr/></td><td align="center" valign="bottom">21<hr/></td><td align="center" valign="bottom">19<hr/></td><td align="center" valign="bottom">25<hr/></td></tr><tr><td align="left" valign="bottom">No. of children not cured after treatment<hr/></td><td align="center" valign="bottom">10<hr/></td><td align="center" valign="bottom">9<hr/></td><td align="center" valign="bottom">11<hr/></td><td align="center" valign="bottom">12<hr/></td></tr><tr><td align="left" valign="bottom">CR, % (95% CI)<hr/></td><td align="center" valign="bottom">60.0<hr/></td><td align="center" valign="bottom">57.1<hr/></td><td align="center" valign="bottom">42.1<hr/></td><td align="center" valign="bottom">52.0<hr/></td></tr><tr><td align="left" valign="bottom">&#x000a0;<hr/></td><td align="center" valign="bottom">(39.4&#x02013;80.6)<hr/></td><td align="center" valign="bottom">(34.1&#x02013;80.2)<hr/></td><td align="center" valign="bottom">(17.7&#x02013;66.6)<hr/></td><td align="center" valign="bottom">(31.0&#x02013;73.0)<hr/></td></tr><tr><td colspan="5" align="left" valign="bottom"><bold><italic>E. histolytica/E. dispar</italic></bold><hr/></td></tr><tr><td align="left" valign="bottom">No. of infected children<hr/></td><td align="center" valign="bottom">23<hr/></td><td align="center" valign="bottom">23<hr/></td><td align="center" valign="bottom">31<hr/></td><td align="center" valign="bottom">22<hr/></td></tr><tr><td align="left" valign="bottom">No. of children not cured after treatment<hr/></td><td align="center" valign="bottom">10<hr/></td><td align="center" valign="bottom">9<hr/></td><td align="center" valign="bottom">10<hr/></td><td align="center" valign="bottom">10<hr/></td></tr><tr><td align="left" valign="bottom">CR, % (95% CI)<hr/></td><td align="center" valign="bottom">56.5<hr/></td><td align="center" valign="bottom">60.9<hr/></td><td align="center" valign="bottom">67.7<hr/></td><td align="center" valign="bottom">54.5<hr/></td></tr><tr><td align="left" valign="bottom">&#x000a0;<hr/></td><td align="center" valign="bottom">(34.6&#x02013;78.4)<hr/></td><td align="center" valign="bottom">(39.3&#x02013;82.4)<hr/></td><td align="center" valign="bottom">(50.3&#x02013;85.2)<hr/></td><td align="center" valign="bottom">(31.9&#x02013;77.1)<hr/></td></tr><tr><td colspan="5" align="left" valign="bottom"><bold><italic>B. hominis</italic></bold><hr/></td></tr><tr><td align="left" valign="bottom">No. of infected children<hr/></td><td align="center" valign="bottom">35<hr/></td><td align="center" valign="bottom">37<hr/></td><td align="center" valign="bottom">33<hr/></td><td align="center" valign="bottom">49<hr/></td></tr><tr><td align="left" valign="bottom">No. of children not cured after treatment<hr/></td><td align="center" valign="bottom">15<hr/></td><td align="center" valign="bottom">16<hr/></td><td align="center" valign="bottom">10<hr/></td><td align="center" valign="bottom">16<hr/></td></tr><tr><td align="left" valign="bottom">CR, % (95% CI)<hr/></td><td align="center" valign="bottom">57.1<hr/></td><td align="center" valign="bottom">56.8<hr/></td><td align="center" valign="bottom">69.7<hr/></td><td align="center" valign="bottom">67.3<hr/></td></tr><tr><td align="left" valign="bottom">&#x000a0;<hr/></td><td align="center" valign="bottom">(39.9&#x02013;74.4)<hr/></td><td align="center" valign="bottom">(40.0&#x02013;73.5)<hr/></td><td align="center" valign="bottom">(53.1&#x02013;86.2)<hr/></td><td align="center" valign="bottom">(53.7&#x02013;81.0)<hr/></td></tr><tr><td colspan="5" align="left" valign="bottom"><bold><italic>E. coli</italic></bold><hr/></td></tr><tr><td align="left" valign="bottom">No. of infected children<hr/></td><td align="center" valign="bottom">75<hr/></td><td align="center" valign="bottom">82<hr/></td><td align="center" valign="bottom">56<hr/></td><td align="center" valign="bottom">70<hr/></td></tr><tr><td align="left" valign="bottom">No. of children not cured after treatment<hr/></td><td align="center" valign="bottom">50<hr/></td><td align="center" valign="bottom">38<hr/></td><td align="center" valign="bottom">27<hr/></td><td align="center" valign="bottom">50<hr/></td></tr><tr><td align="left" valign="bottom">CR, % (95% CI)<hr/></td><td align="center" valign="bottom">33.3<hr/></td><td align="center" valign="bottom">53.7<hr/></td><td align="center" valign="bottom">51.8<hr/></td><td align="center" valign="bottom">28.6<hr/></td></tr><tr><td align="left" valign="bottom">&#x000a0;<hr/></td><td align="center" valign="bottom">(22.4&#x02013;44.3)<hr/></td><td align="center" valign="bottom">(42.6&#x02013;64.7)<hr/></td><td align="center" valign="bottom">(38.3&#x02013;65.3)<hr/></td><td align="center" valign="bottom">(17.7&#x02013;39.4)<hr/></td></tr><tr><td colspan="5" align="left" valign="bottom"><bold><italic>E. hartmanni</italic></bold><hr/></td></tr><tr><td align="left" valign="bottom">No. of infected children<hr/></td><td align="center" valign="bottom">14<hr/></td><td align="center" valign="bottom">22<hr/></td><td align="center" valign="bottom">18<hr/></td><td align="center" valign="bottom">19<hr/></td></tr><tr><td align="left" valign="bottom">No. of children not cured after treatment<hr/></td><td align="center" valign="bottom">5<hr/></td><td align="center" valign="bottom">5<hr/></td><td align="center" valign="bottom">4<hr/></td><td align="center" valign="bottom">7<hr/></td></tr><tr><td align="left" valign="bottom">CR, % (95% CI)<hr/></td><td align="center" valign="bottom">64.3<hr/></td><td align="center" valign="bottom">77.3<hr/></td><td align="center" valign="bottom">77.8<hr/></td><td align="center" valign="bottom">63.2<hr/></td></tr><tr><td align="left" valign="bottom">&#x000a0;<hr/></td><td align="center" valign="bottom">(35.6&#x02013;93.0)<hr/></td><td align="center" valign="bottom">(58.3&#x02013;96.3)<hr/></td><td align="center" valign="bottom">(56.5&#x02013;99.1)<hr/></td><td align="center" valign="bottom">(39.3&#x02013;87.0)<hr/></td></tr><tr><td colspan="5" align="left" valign="bottom"><bold><italic>E. nana</italic></bold><hr/></td></tr><tr><td align="left" valign="bottom">No. of infected children<hr/></td><td align="center" valign="bottom">24<hr/></td><td align="center" valign="bottom">25<hr/></td><td align="center" valign="bottom">23<hr/></td><td align="center" valign="bottom">35<hr/></td></tr><tr><td align="left" valign="bottom">No. of children not cured after treatment<hr/></td><td align="center" valign="bottom">10<hr/></td><td align="center" valign="bottom">9<hr/></td><td align="center" valign="bottom">2<hr/></td><td align="center" valign="bottom">15<hr/></td></tr><tr><td align="left" valign="bottom">CR, % (95% CI)<hr/></td><td align="center" valign="bottom">58.3<hr/></td><td align="center" valign="bottom">64.0<hr/></td><td align="center" valign="bottom">91.3<hr/></td><td align="center" valign="bottom">57.1<hr/></td></tr><tr><td align="left" valign="bottom">&#x000a0;<hr/></td><td align="center" valign="bottom">(37.1&#x02013;79.6)<hr/></td><td align="center" valign="bottom">(43.8&#x02013;84.2)<hr/></td><td align="center" valign="bottom">(78.8&#x02013;100.0)<hr/></td><td align="center" valign="bottom">(39.9&#x02013;74.4)<hr/></td></tr><tr><td colspan="5" align="left" valign="bottom"><bold><italic>C. mesnili</italic></bold><hr/></td></tr><tr><td align="left" valign="bottom">No. of infected children<hr/></td><td align="center" valign="bottom">17<hr/></td><td align="center" valign="bottom">10<hr/></td><td align="center" valign="bottom">6<hr/></td><td align="center" valign="bottom">12<hr/></td></tr><tr><td align="left" valign="bottom">No. of children not cured after treatment<hr/></td><td align="center" valign="bottom">4<hr/></td><td align="center" valign="bottom">1<hr/></td><td align="center" valign="bottom">1<hr/></td><td align="center" valign="bottom">5<hr/></td></tr><tr><td align="left" valign="bottom">CR, % (95% CI)<hr/></td><td align="center" valign="bottom">76.5<hr/></td><td align="center" valign="bottom">90.0<hr/></td><td align="center" valign="bottom">83.3<hr/></td><td align="center" valign="bottom">58.3<hr/></td></tr><tr><td align="left" valign="bottom">&#x000a0;<hr/></td><td align="center" valign="bottom">(54.0&#x02013;99.0)<hr/></td><td align="center" valign="bottom">(67.4&#x02013;100.0)<hr/></td><td align="center" valign="bottom">(40.5&#x02013;100.0)<hr/></td><td align="center" valign="bottom">(25.6&#x02013;91.1)<hr/></td></tr><tr><td colspan="5" align="left" valign="bottom"><bold><italic>I. b&#x000fc;tschlii</italic></bold><hr/></td></tr><tr><td align="left" valign="bottom">No. of infected children<hr/></td><td align="center" valign="bottom">5<hr/></td><td align="center" valign="bottom">13<hr/></td><td align="center" valign="bottom">8<hr/></td><td align="center" valign="bottom">11<hr/></td></tr><tr><td align="left" valign="bottom">No. of children not cured after treatment<hr/></td><td align="center" valign="bottom">1<hr/></td><td align="center" valign="bottom">2<hr/></td><td align="center" valign="bottom">2<hr/></td><td align="center" valign="bottom">4<hr/></td></tr><tr><td align="left" valign="bottom">CR, % (95% CI)<hr/></td><td align="center" valign="bottom">80.0<hr/></td><td align="center" valign="bottom">84.6<hr/></td><td align="center" valign="bottom">75.0<hr/></td><td align="center" valign="bottom">63.6<hr/></td></tr><tr><td align="left">&#x000a0;</td><td align="center">(24.5&#x02013;100.0)</td><td align="center">(61.9&#x02013;100.0)</td><td align="center">(36.3&#x02013;100.0)</td><td align="center">(29.7&#x02013;97.5)</td></tr></tbody></table><table-wrap-foot><p>CI, confidence interval; CR, cure rate.</p></table-wrap-foot></table-wrap><p>Comparing the mean intensity of intestinal protozoa infection before and 3 weeks after treatment in the different arms revealed no significant effect for most of the assessed intestinal protozoa (results not shown). The only significant reductions of infection intensity (95% CI below 0) were observed in the albendazole-nitazoxanide combination against <italic>E. histolytica/E. dispar</italic> (&#x02212;0.21; 95% CI -0.34 to -0.09) and <italic>E. coli</italic> (&#x02212;0.37; 95% CI -0.58 to -0.16) and in the nitazoxanide single-dose treatment against <italic>E. coli</italic> infection intensity (&#x02212;0.37; 95% CI -0.58 to -0.16)<italic>.</italic></p></sec></sec><sec sec-type="discussion"><title>Discussion</title><p>Since very little is known on the epidemiology of intestinal protozoa in sub-Saharan Africa, we analyzed formalin-fixed stool samples obtained from 550 school-aged children who participated in a randomized controlled trial on Pemba Island to assess the efficacy and safety of nitazoxanide, albendazole and a combination of both drugs against <italic>T. trichiura</italic> and other soil-transmitted helminths. This trial found low CRs against soil-transmitted helminth species
[<xref ref-type="bibr" rid="B19">19</xref>]. Importantly, the study provided an opportunity to shed new light on the extent of intestinal protozoa infections in a child cohort and to determine whether the different study treatments had an effect on intestinal protozoa species.</p><p>Our results confirm that intestinal protozoa are a public health issue on Pemba Island. Indeed, almost half of the children were infected with at least one of the three (potentially) pathogenic intestinal protozoa. When considering the results from the baseline and the 3-week post-treatment follow-up, assuming that a child who was diagnosed positive at follow-up was diagnosed as a false-negative case at baseline, the prevalence of intestinal protozoa infection was even higher (Figure&#x02009;
<xref ref-type="fig" rid="F1">1</xref>). This issue is most likely explained by the lack of sensitivity when examining only a single stool sample with the ether-concentration technique, an important limitation of our study. Hence, in future studies, multiple stool samples should be examined and subjected to the ether-concentration method or more sensitive molecular approaches employed to improve diagnostic accuracy 
[<xref ref-type="bibr" rid="B26">26</xref>,<xref ref-type="bibr" rid="B27">27</xref>].</p><p>A recent study reported only moderate sensitivity for the ether-concentration technique compared to the FLOTAC technique when examining the same formalin-fixed stool samples 
[<xref ref-type="bibr" rid="B28">28</xref>]. However, a study among five European reference laboratories showed that the agreement of diagnostic results was only moderate for pathogenic intestinal protozoa although the participating centres adhered to the same standard operating procedures for the ether-concentration technique 
[<xref ref-type="bibr" rid="B21">21</xref>]. In particular, <italic>E. histolytica</italic> is frequently misdiagnosed, even by experienced laboratory personnel 
[<xref ref-type="bibr" rid="B29">29</xref>].</p><p>We found that girls were generally at higher odds of an infection with any of the intestinal protozoa encountered than boys. Similar results were found by Mohammed Mahady and colleagues in Malaysia 
[<xref ref-type="bibr" rid="B30">30</xref>]. On the other hand, Traor&#x000e9; <italic>et al.</italic>, in a study carried out in school-aged children in C&#x000f4;te d&#x02019;Ivoire, reported a considerably higher prevalence of intestinal protozoa among boys than girls 
[<xref ref-type="bibr" rid="B31">31</xref>], corroborating findings by Cifuentes <italic>et al.</italic> from Mexico, where boys were at higher odds of a <italic>G. intestinalis</italic> infection that girls 
[<xref ref-type="bibr" rid="B32">32</xref>]. Other studies found no gender difference at all 
[<xref ref-type="bibr" rid="B33">33</xref>]. These findings indicate that intestinal protozoa infections may be related to gender-specific behaviour within a community. In addition, we observed statistically significant differences for some of the intestinal protozoa between the two schools. Hence, even though the schools are located only a few kilometers apart and the two settings were quite similar, at least in terms of socioeconomic status, availability of safe water supply and sanitation infrastructure, different infection profiles were observed. This highlights the possibility of &#x02018;micro-geographic&#x02019; variability in endemicity of intestinal protozoa infection. One explanation could be that Al-Sadik school is located close to an orphanage, where transmission of intestinal protozoa might be enhanced. Other behavioural, infrastructure or environmental factors that may account for our observation should be investigated in future studies.</p><p>Intestinal protozoa often co-occur with intestinal nematodes and it is therefore important to determine whether anthelminthic and other antiparasitic drugs have an effect on concomitant intestinal protozoa infections. Albendazole, for example, was found in a recent meta-analysis to be as effective as metronidazole against <italic>G. intestinalis</italic>[<xref ref-type="bibr" rid="B34">34</xref>]. The observed CRs against all intestinal protozoa were moderate to high in the three treatment groups. However &#x02013; and contrary to what we expected &#x02013; there was also a moderate treatment efficacy in the placebo group, which is difficult to explain other than a diagnostic dilemma. Our findings therefore have to be interpreted with caution. The high &#x02018;cure rate&#x02019; observed within the placebo group underscores that analysis of a single stool sample with the formalin-ether concentration technique is unreliable, and hence, the CRs for the three treatment schemes investigated here are likely overestimated. Still, our results show that none of the drugs administered as single dose resulted in cure of all infected children. Only moderate CRs were observed against <italic>G. intestinalis</italic>, <italic>E. histolytica/E. dispar</italic> and the potentially pathogenic <italic>B. hominis.</italic> A further limitation is the relatively small number of positive children for specific intestinal protozoa. Infection intensity did not significantly decrease after treatment with the exception of <italic>E. coli</italic> in the nitazoxanide group. Note that intestinal protozoa multiply within the host, which can also influence infection intensity results 
[<xref ref-type="bibr" rid="B35">35</xref>]. Further, the incubation time for different intestinal protozoa is between 7 and 28 days, meaning that it is possible that within the 3-week period before and after treatment, re-infection had occured 
[<xref ref-type="bibr" rid="B36">36</xref>-<xref ref-type="bibr" rid="B40">40</xref>]. The clinical relevance of the moderate CRs suggests that single-dose albendazole or nitazoxanide or a combination of the two drugs do not have sufficient efficacy against pathogenic intestinal protozoa. However, multiple stool samples should be examined to strengthen the diagnostic accuracy for these infections.</p></sec><sec sec-type="conclusions"><title>Conclusion</title><p>Our study revealed that intestinal protozoa infections are highly prevalent among school-aged children on Pemba Island, a setting where these intestinal protozoa were not considered of major importance thus far. The difficulty in accurately diagnosing intestinal protozoa infections, also experienced in our study, might be one of the chief reasons why these pathogens and the diseases they cause are often neglected, even in settings where mass treatment are underway against intestinal helminth infections 
[<xref ref-type="bibr" rid="B21">21</xref>]. The prevalence of intestinal protozoa is therefore unknown in many settings and consequently the disease burden cannot be fully quantified 
[<xref ref-type="bibr" rid="B41">41</xref>]. Accurate diagnostic tools that can be applied at the point-of-care are thus urgently required. Finally, drugs and effective treatment regimens for intestinal protozoa infections to be used in public health campaigns are still far out of reach.</p></sec><sec><title>Competing interests</title><p>None of the authors has any conflict of interest concerning the work reported in this paper.</p></sec><sec><title>Authors&#x02019; contributions</title><p>BS, ShMA, SaMA, JU, MA and JK designed the study; BS, HM, ShMA, SaMA, and JK implemented the study; BS managed the data; BS, HM, IIB, JU and JK analyzed and interpreted the data; BS wrote the first draft of the paper; HM, ShMA, SaMA, IIB, JU, MA and JK revised the manuscript. All authors read, and approved the manuscript prior to submission and assisted with the final revision of the manuscript.</p></sec></body><back><ref-list><ref id="B1"><mixed-citation publication-type="journal"><name><surname>Feng</surname><given-names>Y</given-names></name><name><surname>Xiao</surname><given-names>L</given-names></name><article-title>Zoonotic potential and molecular epidemiology of Giardia species and giardiasis</article-title><source>Clin Microbiol Rev</source><year>2011</year><volume>24</volume><fpage>110</fpage><lpage>140</lpage><pub-id pub-id-type="doi">10.1128/CMR.00033-10</pub-id><pub-id pub-id-type="pmid">21233509</pub-id></mixed-citation></ref><ref id="B2"><mixed-citation publication-type="journal"><name><surname>Stanley</surname><given-names>SL</given-names></name><article-title>Amoebiasis</article-title><source>Lancet</source><year>2003</year><volume>361</volume><fpage>1025</fpage><lpage>1034</lpage><pub-id pub-id-type="doi">10.1016/S0140-6736(03)12830-9</pub-id><pub-id pub-id-type="pmid">12660071</pub-id></mixed-citation></ref><ref id="B3"><mixed-citation publication-type="journal"><name><surname>Lozano</surname><given-names>R</given-names></name><name><surname>Naghavi</surname><given-names>M</given-names></name><name><surname>Foreman</surname><given-names>K</given-names></name><name><surname>Lim</surname><given-names>S</given-names></name><name><surname>Shibuya</surname><given-names>K</given-names></name><name><surname>Aboyans</surname><given-names>V</given-names></name><name><surname>Abraham</surname><given-names>J</given-names></name><name><surname>Adair</surname><given-names>T</given-names></name><name><surname>Aggarwal</surname><given-names>R</given-names></name><name><surname>Ahn</surname><given-names>SY</given-names></name><etal/><article-title>Global and regional mortality from 235 causes of death for 20 age groups in 1990 and 2010: a systematic analysis for the Global Burden of Disease Study 2010</article-title><source>Lancet</source><year>2012</year><volume>380</volume><fpage>2095</fpage><lpage>2128</lpage><pub-id pub-id-type="doi">10.1016/S0140-6736(12)61728-0</pub-id><pub-id pub-id-type="pmid">23245604</pub-id></mixed-citation></ref><ref id="B4"><mixed-citation publication-type="journal"><name><surname>Escobedo</surname><given-names>AA</given-names></name><name><surname>Cimerman</surname><given-names>S</given-names></name><article-title>Giardiasis: a pharmacotherapy review</article-title><source>Expert Opin Pharmacother</source><year>2007</year><volume>8</volume><fpage>1885</fpage><lpage>1902</lpage><pub-id pub-id-type="doi">10.1517/14656566.8.12.1885</pub-id><pub-id pub-id-type="pmid">17696791</pub-id></mixed-citation></ref><ref id="B5"><mixed-citation publication-type="journal"><name><surname>Jex</surname><given-names>AR</given-names></name><name><surname>Smith</surname><given-names>HV</given-names></name><name><surname>Nolan</surname><given-names>MJ</given-names></name><name><surname>Campbell</surname><given-names>BE</given-names></name><name><surname>Young</surname><given-names>ND</given-names></name><name><surname>Cantacessi</surname><given-names>C</given-names></name><name><surname>Gasser</surname><given-names>RB</given-names></name><article-title>Cryptic parasite revealed improved prospects for treatment and control of human cryptosporidiosis through advanced technologies</article-title><source>Adv Parasitol</source><year>2011</year><volume>77</volume><fpage>141</fpage><lpage>173</lpage><pub-id pub-id-type="pmid">22137584</pub-id></mixed-citation></ref><ref id="B6"><mixed-citation publication-type="journal"><name><surname>Davies</surname><given-names>AP</given-names></name><name><surname>Chalmers</surname><given-names>RM</given-names></name><article-title>Cryptosporidiosis</article-title><source>BMJ</source><year>2009</year><volume>339</volume><fpage>b4168</fpage><pub-id pub-id-type="doi">10.1136/bmj.b4168</pub-id><pub-id pub-id-type="pmid">19841008</pub-id></mixed-citation></ref><ref id="B7"><mixed-citation publication-type="journal"><name><surname>Stensvold</surname><given-names>CR</given-names></name><name><surname>Lewis</surname><given-names>HC</given-names></name><name><surname>Hammerum</surname><given-names>AM</given-names></name><name><surname>Porsbo</surname><given-names>LJ</given-names></name><name><surname>Nielsen</surname><given-names>SS</given-names></name><name><surname>Olsen</surname><given-names>KE</given-names></name><name><surname>Arendrup</surname><given-names>MC</given-names></name><name><surname>Nielsen</surname><given-names>HV</given-names></name><name><surname>M&#x000f8;lbak</surname><given-names>K</given-names></name><article-title>Blastocystis: unravelling potential risk factors and clinical significance of a common but neglected parasite</article-title><source>Epidemiol Infect</source><year>2009</year><volume>137</volume><fpage>1655</fpage><lpage>1663</lpage><pub-id pub-id-type="doi">10.1017/S0950268809002672</pub-id><pub-id pub-id-type="pmid">19393117</pub-id></mixed-citation></ref><ref id="B8"><mixed-citation publication-type="journal"><name><surname>Leder</surname><given-names>K</given-names></name><name><surname>Hellard</surname><given-names>ME</given-names></name><name><surname>Sinclair</surname><given-names>MI</given-names></name><name><surname>Fairley</surname><given-names>CK</given-names></name><name><surname>Wolfe</surname><given-names>R</given-names></name><article-title>No correlation between clinical symptoms and Blastocystis hominis in immunocompetent individuals</article-title><source>J Gastroenterol Hepatol</source><year>2005</year><volume>20</volume><fpage>1390</fpage><lpage>1394</lpage><pub-id pub-id-type="doi">10.1111/j.1440-1746.2005.03868.x</pub-id><pub-id pub-id-type="pmid">16105126</pub-id></mixed-citation></ref><ref id="B9"><mixed-citation publication-type="journal"><name><surname>Sheehan</surname><given-names>DJ</given-names></name><name><surname>Raucher</surname><given-names>BG</given-names></name><name><surname>McKitrick</surname><given-names>JC</given-names></name><article-title>Association of Blastocystis hominis with signs and symptoms of human disease</article-title><source>J Clin Microbiol</source><year>1986</year><volume>24</volume><fpage>548</fpage><lpage>550</lpage><pub-id pub-id-type="pmid">3771743</pub-id></mixed-citation></ref><ref id="B10"><mixed-citation publication-type="journal"><name><surname>Yoder</surname><given-names>JS</given-names></name><name><surname>Harral</surname><given-names>C</given-names></name><name><surname>Beach</surname><given-names>MJ</given-names></name><article-title>Giardiasis surveillance-United States, 2006&#x02013;2008</article-title><source>MMWR Surveill Summ</source><year>2010</year><volume>59</volume><fpage>15</fpage><lpage>25</lpage><pub-id pub-id-type="pmid">20535095</pub-id></mixed-citation></ref><ref id="B11"><mixed-citation publication-type="journal"><name><surname>Hellard</surname><given-names>ME</given-names></name><name><surname>Sinclair</surname><given-names>MI</given-names></name><name><surname>Hogg</surname><given-names>GG</given-names></name><name><surname>Fairley</surname><given-names>CK</given-names></name><article-title>Prevalence of enteric pathogens among community based asymptomatic individuals</article-title><source>J Gastroenterol Hepatol</source><year>2000</year><volume>15</volume><fpage>290</fpage><lpage>293</lpage><pub-id pub-id-type="doi">10.1046/j.1440-1746.2000.02089.x</pub-id><pub-id pub-id-type="pmid">10764030</pub-id></mixed-citation></ref><ref id="B12"><mixed-citation publication-type="journal"><name><surname>Taylor</surname><given-names>DN</given-names></name><name><surname>Houston</surname><given-names>R</given-names></name><name><surname>Shlim</surname><given-names>DR</given-names></name><name><surname>Bhaibulaya</surname><given-names>M</given-names></name><name><surname>Ungar</surname><given-names>BL</given-names></name><name><surname>Echeverria</surname><given-names>P</given-names></name><article-title>Etiology of diarrhea among travelers and foreign residents in Nepal</article-title><source>JAMA</source><year>1988</year><volume>260</volume><fpage>1245</fpage><lpage>1248</lpage><pub-id pub-id-type="doi">10.1001/jama.1988.03410090077034</pub-id><pub-id pub-id-type="pmid">3404637</pub-id></mixed-citation></ref><ref id="B13"><mixed-citation publication-type="journal"><name><surname>Escobedo</surname><given-names>AA</given-names></name><name><surname>Almirall</surname><given-names>P</given-names></name><name><surname>Alfonso</surname><given-names>M</given-names></name><name><surname>Cimerman</surname><given-names>S</given-names></name><name><surname>Rey</surname><given-names>S</given-names></name><name><surname>Terry</surname><given-names>SL</given-names></name><article-title>Treatment of intestinal protozoan infections in children</article-title><source>Arch Dis Child</source><year>2009</year><volume>94</volume><fpage>478</fpage><lpage>482</lpage><pub-id pub-id-type="doi">10.1136/adc.2008.151852</pub-id><pub-id pub-id-type="pmid">19329448</pub-id></mixed-citation></ref><ref id="B14"><mixed-citation publication-type="journal"><name><surname>Rodriguez-Garcia</surname><given-names>R</given-names></name><name><surname>Rodriguez-Guzman</surname><given-names>LM</given-names></name><name><surname>Cruz del Castillo</surname><given-names>AH</given-names></name><article-title>Effectiveness and safety of mebendazole compared to nitazoxanide in the treatment of Giardia lamblia in children</article-title><source>Rev Gastroenterol Mex</source><year>1999</year><volume>64</volume><fpage>122</fpage><lpage>126</lpage><pub-id pub-id-type="pmid">10532139</pub-id></mixed-citation></ref><ref id="B15"><mixed-citation publication-type="journal"><name><surname>Yereli</surname><given-names>K</given-names></name><name><surname>Balcioglu</surname><given-names>IC</given-names></name><name><surname>Ertan</surname><given-names>P</given-names></name><name><surname>Limoncu</surname><given-names>E</given-names></name><name><surname>Onag</surname><given-names>A</given-names></name><article-title>Albendazole as an alternative therapeutic agent for childhood giardiasis in Turkey</article-title><source>Clin Microbiol Infect</source><year>2004</year><volume>10</volume><fpage>527</fpage><lpage>529</lpage><pub-id pub-id-type="doi">10.1111/j.1198-743X.2004.00829.x</pub-id><pub-id pub-id-type="pmid">15191380</pub-id></mixed-citation></ref><ref id="B16"><mixed-citation publication-type="journal"><name><surname>Ortiz</surname><given-names>JJ</given-names></name><name><surname>Ayoub</surname><given-names>A</given-names></name><name><surname>Gargala</surname><given-names>G</given-names></name><name><surname>Chegne</surname><given-names>NL</given-names></name><name><surname>Favennec</surname><given-names>L</given-names></name><article-title>Randomized clinical study of nitazoxanide compared to metronidazole in the treatment of symptomatic giardiasis in children from northern Peru</article-title><source>Aliment Pharmacol Ther</source><year>2001</year><volume>15</volume><fpage>1409</fpage><lpage>1415</lpage><pub-id pub-id-type="doi">10.1046/j.1365-2036.2001.01066.x</pub-id><pub-id pub-id-type="pmid">11552913</pub-id></mixed-citation></ref><ref id="B17"><mixed-citation publication-type="journal"><name><surname>Pampiglione</surname><given-names>S</given-names></name><name><surname>Visconti</surname><given-names>S</given-names></name><name><surname>Stefanini</surname><given-names>A</given-names></name><article-title>Human intestinal parasites in sub-Saharan Africa. III. Pemba Island (Zanzibar-Tanzania)</article-title><source>Parassitologia</source><year>1987</year><volume>29</volume><fpage>27</fpage><lpage>35</lpage><comment>in Italian</comment><pub-id pub-id-type="pmid">3508507</pub-id></mixed-citation></ref><ref id="B18"><mixed-citation publication-type="journal"><name><surname>Albonico</surname><given-names>M</given-names></name><name><surname>De Carneri</surname><given-names>I</given-names></name><name><surname>Di Matteo</surname><given-names>L</given-names></name><name><surname>Ghiglietti</surname><given-names>R</given-names></name><name><surname>Toscano</surname><given-names>P</given-names></name><name><surname>Uledi</surname><given-names>MK</given-names></name><name><surname>Savioli</surname><given-names>L</given-names></name><article-title>Intestinal parasitic infections of urban and rural children on Pemba Island: implications for control</article-title><source>Ann Trop Med Parasitol</source><year>1993</year><volume>87</volume><fpage>579</fpage><lpage>583</lpage><pub-id pub-id-type="pmid">8122919</pub-id></mixed-citation></ref><ref id="B19"><mixed-citation publication-type="journal"><name><surname>Speich</surname><given-names>B</given-names></name><name><surname>Ame</surname><given-names>SM</given-names></name><name><surname>Ali</surname><given-names>SM</given-names></name><name><surname>Alles</surname><given-names>R</given-names></name><name><surname>Hattendorf</surname><given-names>J</given-names></name><name><surname>Utzinger</surname><given-names>J</given-names></name><name><surname>Albonico</surname><given-names>M</given-names></name><name><surname>Keiser</surname><given-names>J</given-names></name><article-title>Efficacy and safety of nitazoxanide, albendazole, and nitazoxanide-albendazole against Trichuris trichiura infection: a randomized controlled trial</article-title><source>PLoS Negl Trop Dis</source><year>2012</year><volume>6</volume><fpage>e1685</fpage><pub-id pub-id-type="doi">10.1371/journal.pntd.0001685</pub-id><pub-id pub-id-type="pmid">22679525</pub-id></mixed-citation></ref><ref id="B20"><mixed-citation publication-type="journal"><name><surname>Marti</surname><given-names>H</given-names></name><name><surname>Escher</surname><given-names>E</given-names></name><article-title>SAF-an alternative fixation solution for parasitological stool specimens</article-title><source>Schweiz Med Wochenschr</source><year>1990</year><volume>120</volume><fpage>1473</fpage><lpage>1476</lpage><comment>in German</comment><pub-id pub-id-type="pmid">2218469</pub-id></mixed-citation></ref><ref id="B21"><mixed-citation publication-type="journal"><name><surname>Utzinger</surname><given-names>J</given-names></name><name><surname>Botero-Kleiven</surname><given-names>S</given-names></name><name><surname>Castelli</surname><given-names>F</given-names></name><name><surname>Chiodini</surname><given-names>PL</given-names></name><name><surname>Edwards</surname><given-names>H</given-names></name><name><surname>Kohler</surname><given-names>N</given-names></name><name><surname>Gulletta</surname><given-names>M</given-names></name><name><surname>Lebbad</surname><given-names>M</given-names></name><name><surname>Manser</surname><given-names>M</given-names></name><name><surname>Matthys</surname><given-names>B</given-names></name><etal/><article-title>Microscopic diagnosis of sodium acetate-acetic acid-formalin-fixed stool samples for helminths and intestinal protozoa: a comparison among European reference laboratories</article-title><source>Clin Microbiol Infect</source><year>2010</year><volume>16</volume><fpage>267</fpage><lpage>273</lpage><pub-id pub-id-type="doi">10.1111/j.1469-0691.2009.02782.x</pub-id><pub-id pub-id-type="pmid">19456836</pub-id></mixed-citation></ref><ref id="B22"><mixed-citation publication-type="journal"><name><surname>Diamond</surname><given-names>LS</given-names></name><name><surname>Clark</surname><given-names>CG</given-names></name><article-title>A redescription of Entamoeba histolytica Schaudinn, 1903 (Emended Walker, 1911) separating it from Entamoeba dispar Brumpt, 1925</article-title><source>J Eukaryot Microbiol</source><year>1993</year><volume>40</volume><fpage>340</fpage><lpage>344</lpage><pub-id pub-id-type="doi">10.1111/j.1550-7408.1993.tb04926.x</pub-id><pub-id pub-id-type="pmid">8508172</pub-id></mixed-citation></ref><ref id="B23"><mixed-citation publication-type="journal"><name><surname>Pierce</surname><given-names>KK</given-names></name><name><surname>Kirkpatrick</surname><given-names>BD</given-names></name><article-title>Update on human infections caused by intestinal protozoa</article-title><source>Curr Opin Gastroenterol</source><year>2009</year><volume>25</volume><fpage>12</fpage><lpage>17</lpage><pub-id pub-id-type="doi">10.1097/MOG.0b013e32831da7dd</pub-id><pub-id pub-id-type="pmid">19119509</pub-id></mixed-citation></ref><ref id="B24"><mixed-citation publication-type="journal"><name><surname>Leitch</surname><given-names>GJ</given-names></name><name><surname>He</surname><given-names>Q</given-names></name><article-title>Cryptosporidiosis-an overview</article-title><source>J Biomed Res</source><year>2012</year><volume>25</volume><fpage>1</fpage><lpage>16</lpage><pub-id pub-id-type="doi">10.1016/S1674-8301(11)60001-8</pub-id><pub-id pub-id-type="pmid">22685452</pub-id></mixed-citation></ref><ref id="B25"><mixed-citation publication-type="journal"><name><surname>Coulibaly</surname><given-names>JT</given-names></name><name><surname>F&#x000fc;rst</surname><given-names>T</given-names></name><name><surname>Silu&#x000e9;</surname><given-names>KD</given-names></name><name><surname>Knopp</surname><given-names>S</given-names></name><name><surname>Hauri</surname><given-names>D</given-names></name><name><surname>Ouattara</surname><given-names>M</given-names></name><name><surname>Utzinger</surname><given-names>J</given-names></name><name><surname>N&#x02019;Goran</surname><given-names>EK</given-names></name><article-title>Intestinal parasitic infections in schoolchildren in different settings of C&#x000f4;te d&#x02019;Ivoire: effect of diagnostic approach and implications for control</article-title><source>Parasit Vectors</source><year>2012</year><volume>5</volume><fpage>135</fpage><pub-id pub-id-type="doi">10.1186/1756-3305-5-135</pub-id><pub-id pub-id-type="pmid">22768986</pub-id></mixed-citation></ref><ref id="B26"><mixed-citation publication-type="journal"><name><surname>Marti</surname><given-names>H</given-names></name><name><surname>Koella</surname><given-names>JC</given-names></name><article-title>Multiple stool examinations for ova and parasites and rate of false-negative results</article-title><source>J Clin Microbiol</source><year>1993</year><volume>31</volume><fpage>3044</fpage><lpage>3045</lpage><pub-id pub-id-type="pmid">8263196</pub-id></mixed-citation></ref><ref id="B27"><mixed-citation publication-type="journal"><name><surname>van Lieshout</surname><given-names>L</given-names></name><name><surname>Verweij</surname><given-names>JJ</given-names></name><article-title>Newer diagnostic approaches to intestinal protozoa</article-title><source>Curr Opin Infect Dis</source><year>2010</year><volume>23</volume><fpage>488</fpage><lpage>493</lpage><pub-id pub-id-type="doi">10.1097/QCO.0b013e32833de0eb</pub-id><pub-id pub-id-type="pmid">20683263</pub-id></mixed-citation></ref><ref id="B28"><mixed-citation publication-type="journal"><name><surname>Becker</surname><given-names>SL</given-names></name><name><surname>Lohourignon</surname><given-names>LK</given-names></name><name><surname>Speich</surname><given-names>B</given-names></name><name><surname>Rinaldi</surname><given-names>L</given-names></name><name><surname>Knopp</surname><given-names>S</given-names></name><name><surname>N&#x02019;Goran</surname><given-names>EK</given-names></name><name><surname>Cringoli</surname><given-names>G</given-names></name><name><surname>Utzinger</surname><given-names>J</given-names></name><article-title>Comparison of the Flotac-400 dual technique and the formalin-ether concentration technique for diagnosis of human intestinal protozoon infection</article-title><source>J Clin Microbiol</source><year>2011</year><volume>49</volume><fpage>2183</fpage><lpage>2190</lpage><pub-id pub-id-type="doi">10.1128/JCM.01035-10</pub-id><pub-id pub-id-type="pmid">21525226</pub-id></mixed-citation></ref><ref id="B29"><mixed-citation publication-type="journal"><name><surname>Rayan</surname><given-names>HZE</given-names></name><article-title>Microscopic overdiagnosis of intestinal amoebiasis</article-title><source>J Egypt Soc Parasitol</source><year>2005</year><volume>35</volume><fpage>941</fpage><lpage>951</lpage><pub-id pub-id-type="pmid">16333901</pub-id></mixed-citation></ref><ref id="B30"><mixed-citation publication-type="journal"><name><surname>Mohammed Mahdy</surname><given-names>AK</given-names></name><name><surname>Surin</surname><given-names>J</given-names></name><name><surname>Wan</surname><given-names>KL</given-names></name><name><surname>Mohd-Adnan</surname><given-names>A</given-names></name><name><surname>Hesham Al-Mekhlafi</surname><given-names>MS</given-names></name><name><surname>Lim</surname><given-names>YAL</given-names></name><article-title>Giardia intestinalis genotypes: risk factors and correlation with clinical symptoms</article-title><source>Acta Trop</source><year>2009</year><volume>112</volume><fpage>67</fpage><lpage>70</lpage><pub-id pub-id-type="doi">10.1016/j.actatropica.2009.06.012</pub-id><pub-id pub-id-type="pmid">19560431</pub-id></mixed-citation></ref><ref id="B31"><mixed-citation publication-type="journal"><name><surname>Traor&#x000e9;</surname><given-names>SG</given-names></name><name><surname>Odermatt</surname><given-names>P</given-names></name><name><surname>Bonfoh</surname><given-names>B</given-names></name><name><surname>Utzinger</surname><given-names>J</given-names></name><name><surname>Aka</surname><given-names>ND</given-names></name><name><surname>Adoubryn</surname><given-names>KD</given-names></name><name><surname>Assoumou</surname><given-names>A</given-names></name><name><surname>Dreyfuss</surname><given-names>G</given-names></name><name><surname>Kouss&#x000e9;mon</surname><given-names>M</given-names></name><article-title>No Paragonimus in high-risk groups in C&#x000f4;te d'Ivoire, but considerable prevalence of helminths and intestinal protozoon infections</article-title><source>Parasit Vectors</source><year>2011</year><volume>4</volume><fpage>96</fpage><pub-id pub-id-type="doi">10.1186/1756-3305-4-96</pub-id><pub-id pub-id-type="pmid">21639877</pub-id></mixed-citation></ref><ref id="B32"><mixed-citation publication-type="journal"><name><surname>Cifuentes</surname><given-names>E</given-names></name><name><surname>Suarez</surname><given-names>L</given-names></name><name><surname>Espinosa</surname><given-names>M</given-names></name><name><surname>Juarez-Figueroa</surname><given-names>L</given-names></name><name><surname>Martinez-Palomo</surname><given-names>A</given-names></name><article-title>Risk of Giardia intestinalis infection in children from an artificially recharged groundwater area in Mexico City</article-title><source>Am J Trop Med Hyg</source><year>2004</year><volume>71</volume><fpage>65</fpage><lpage>70</lpage><pub-id pub-id-type="pmid">15238691</pub-id></mixed-citation></ref><ref id="B33"><mixed-citation publication-type="journal"><name><surname>Prado</surname><given-names>MS</given-names></name><name><surname>Strina</surname><given-names>A</given-names></name><name><surname>Barreto</surname><given-names>ML</given-names></name><name><surname>Oliveira-Assis</surname><given-names>AM</given-names></name><name><surname>Paz</surname><given-names>LM</given-names></name><name><surname>Cairncross</surname><given-names>S</given-names></name><article-title>Risk factors for infection with Giardia duodenalis in pre-school children in the city of Salvador, Brazil</article-title><source>Epidemiol Infect</source><year>2003</year><volume>131</volume><fpage>899</fpage><lpage>906</lpage><pub-id pub-id-type="doi">10.1017/S0950268803001018</pub-id><pub-id pub-id-type="pmid">14596531</pub-id></mixed-citation></ref><ref id="B34"><mixed-citation publication-type="journal"><name><surname>Solaymani-Mohammadi</surname><given-names>S</given-names></name><name><surname>Genkinger</surname><given-names>JM</given-names></name><name><surname>Loffredo</surname><given-names>CA</given-names></name><name><surname>Singer</surname><given-names>SM</given-names></name><article-title>A meta-analysis of the effectiveness of albendazole compared with metronidazole as treatments for infections with Giardia duodenalis</article-title><source>PLoS Negl Trop Dis</source><year>2010</year><volume>4</volume><fpage>e682</fpage><pub-id pub-id-type="doi">10.1371/journal.pntd.0000682</pub-id><pub-id pub-id-type="pmid">20485492</pub-id></mixed-citation></ref><ref id="B35"><mixed-citation publication-type="journal"><name><surname>Wright</surname><given-names>SG</given-names></name><article-title>Protozoan infections of the gastrointestinal tract</article-title><source>Infect Dis Clin North Am</source><year>2012</year><volume>26</volume><fpage>323</fpage><lpage>339</lpage><pub-id pub-id-type="doi">10.1016/j.idc.2012.03.009</pub-id><pub-id pub-id-type="pmid">22632642</pub-id></mixed-citation></ref><ref id="B36"><mixed-citation publication-type="journal"><name><surname>Rendtorff</surname><given-names>RC</given-names></name><article-title>The experimental transmission of human intestinal protozoan parasites. II. Giardia lambliacysts given in capsules.</article-title><source>Am J Hyg</source><year>1954</year><volume>59</volume><fpage>209</fpage><lpage>220</lpage><pub-id pub-id-type="pmid">13138586</pub-id></mixed-citation></ref><ref id="B37"><mixed-citation publication-type="journal"><name><surname>Rendtorff</surname><given-names>RC</given-names></name><name><surname>Holt</surname><given-names>CJ</given-names></name><article-title>The experimental transmission of human intestinal protozoan parasites. IV. Attempts to transmitEndamoeba coliandGiardia lambliacysts by water.</article-title><source>Am J Hyg</source><year>1954</year><volume>60</volume><fpage>327</fpage><lpage>338</lpage><pub-id pub-id-type="pmid">13207103</pub-id></mixed-citation></ref><ref id="B38"><mixed-citation publication-type="journal"><name><surname>Jokipii</surname><given-names>AM</given-names></name><name><surname>Hemil&#x000e4;</surname><given-names>M</given-names></name><name><surname>Jokipii</surname><given-names>L</given-names></name><article-title>Prospective study of acquisition of Cryptosporidium, Giardia lamblia, and gastrointestinal illness</article-title><source>Lancet</source><year>1985</year><volume>326</volume><fpage>487</fpage><lpage>489</lpage><pub-id pub-id-type="doi">10.1016/S0140-6736(85)90412-X</pub-id><pub-id pub-id-type="pmid">2863502</pub-id></mixed-citation></ref><ref id="B39"><mixed-citation publication-type="book"><name><surname>Katz</surname><given-names>M</given-names></name><name><surname>Despammier</surname><given-names>DD</given-names></name><name><surname>Gwadz</surname><given-names>RW</given-names></name><source>Parasitic Diseases</source><year>1989</year><publisher-name>New York, N.Y: Springer</publisher-name></mixed-citation></ref><ref id="B40"><mixed-citation publication-type="book"><name><surname>Garcia</surname><given-names>LS</given-names></name><name><surname>Bruckner</surname><given-names>DA</given-names></name><source>Diagnostic Medical Parasitology</source><year>1997</year><edition>3</edition><publisher-name>Washington, D.C.: ASM Press</publisher-name></mixed-citation></ref><ref id="B41"><mixed-citation publication-type="journal"><name><surname>Okhuysen</surname><given-names>PC</given-names></name><article-title>Traveler&#x02019;s diarrhea due to intestinal protozoa</article-title><source>Clin Infect Dis</source><year>2001</year><volume>33</volume><fpage>110</fpage><lpage>114</lpage><pub-id pub-id-type="doi">10.1086/320894</pub-id><pub-id pub-id-type="pmid">11389503</pub-id></mixed-citation></ref></ref-list></back></article>